Atlas Trials

The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

Clinical trial NCT04517227 · UNKNOWN

Trial details

NCT number
NCT04517227
Sponsor
Fudan University
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2021-07-01
Primary completion
2025-06-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.